Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) reported Monday that its ongoing gene therapy trial in elderly dogs has shown no adverse effects since treatment administration in March.
The randomized, controlled trial, which involves 28 beagles aged 10 years and older, is testing three different modalities of the company’s SIRT6-centenarian gene therapy. The dogs will now enter a five-month follow-up period expected to conclude in January 2026.
According to the company’s press release statement, the trial aims to evaluate the safety and efficacy of Genflow’s GF-1004 therapy, which targets aging mechanisms shared by both dogs and humans. The study is measuring multiple outcomes including biological age reduction, increased muscle strength, enhanced mitochondrial function, improved coat quality, and overall health metrics.
Dr. Eric Leire, CEO of Genflow, said: "Now that all dogs have received the treatment without any adverse events, we’ve taken an important step in confirming the treatment’s safety profile."
The company stated that the strategic goal of this proof-of-concept trial is to generate preclinical data that could enable a licensing agreement with an animal health company.
Genflow Biosciences describes itself as the only publicly listed longevity company in Europe. The trial is being conducted with contract research organization Syngene.
The company’s lead compound, GF-1002, works through delivery of a centenarian variant of the SIRT6 gene. Genflow also plans to explore potential benefits of GF-1002 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a chronic liver disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.